Current and future pharmacological therapies for NAFLD/NASH.
Sumida Y, Yoneda M. · 2018
Read Current and future pharmacological therapies for NAFLD/NASH. by Sumida Y, Yoneda M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5847174.txt.
Description
Sumida and Yoneda survey the hunt for a drug against fatty liver disease. Their review appeared in the Journal of Gastroenterology. No medicine is yet approved for NAFLD or its fiercer form, NASH. Vitamin E and pioglitazone help some NASH patients today.
Diabetes drugs like GLP-1 agonists show early promise. New candidates attack four fronts in the disease. Some curb fat buildup or oxidative stress. Others target gut microbes or the scarring that kills. Four agents have reached phase 3 trials worldwide. The authors expect real choices within a few years.
Catalog record
| CREATOR | Sumida Y, Yoneda M. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |